GHTM

Global Health and Tropical Medicine

  • GHTM
    • About GHTM
    • Governance
    • Impact
    • Members
    • Scientific Advisory Board
    • Reports
      • GHTM
  • Research
    • Cross-cutting issues
      • Antimicrobial Resistance and Drug Discovery
      • Host–Pathogen Interactions
      • Genomic Surveillance and Population Mobility
      • Implementation and Translational Research
      • Information for Health Development
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • PRIME – Pathogen resistance, infection and molecular epidemiology
      • VBD – Vector borne diseases
      • CTM – Clinical tropical medicine
    • Research in numbers
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
    • Projects
      • Ongoing Projects
      • Completed Projects
  • Outreach
    • Events
    • News
    • Policy Support & Community Outreach
  • Publications
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
  • Capacity Building
    • Education
      • Master Theses
      • PhD Theses
    • International
  • Infrastructures
    • BIOHUB & Available Software
    • BIOTROP Biobank
    • VIASEF & Insectaries
  • Networks & Partnerships
Home / Publications / Genotyping of Pneumocystis jirovecii in colonized patients with various pulmonary diseases

Genotyping of Pneumocystis jirovecii in colonized patients with various pulmonary diseases

  • Authors: Sokulska M, Kicia M, Wesolowska M, Piesiak P, Kowal A, Lobo ML, Kopacz Z, Hendrich AB, Matos O
  • Publication Year: 2018
  • Journal: Medical Mycology
  • Link: https://www.ncbi.nlm.nih.gov/pubmed/29228377

Pneumocystis jirovecii is an opportunistic fungus causing Pneumocystis pneumonia primarily in immunosuppressed patients. However, immunocompetent individuals may become colonized and, as asymptomatic carriers, serve as reservoirs of the pathogen. Moreover, these asymptomatic carriers are at higher risk of developing pneumonia if favorable conditions occur. This study aimed to determine the prevalence of P. jirovecii in patients with various pulmonary diseases and to characterize the genetic diversity of organisms circulating in the studied population. Bronchial washing specimens from 105 patients were tested for presence of P. jirovecii using nested polymerase chain reaction (PCR) targeting the mtLSU rRNA gene, as well as immunofluorescence microscopy. Multilocus sequence typing involving analysis of three loci-mtLSU rRNA, CYB, and SOD-was used for genotyping analysis. P. jirovecii DNA was detected in 17 (16.2%) patients. Amplification of the SOD locus was successful only in five cases (29.4% of the positive patients), while mtLSU rRNA and CYB were genotyped in all positive samples. Therefore, combined genotypes were identified based only on mtLSU rRNA and CYB loci. Eight different genotypes were identified, with Pj 1 and Pj 2 being the most prevalent (29.4% of patients each). There was no statistical correlation between these genotypes and demographic or clinical data; however, we found that infection with mutant CYB strains occurred only in patients diagnosed with lung cancer. Of the potential predictors examined, only immunosuppressive treatment was significantly associated with colonization. In conclusion, patients with various respiratory diseases, especially when immunosuppressed, are at risk of Pneumocystis colonization.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Pinterest (Opens in new window) Pinterest
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Print (Opens in new window) Print

About GHTM

GHTM is a R&D Unit that brings together researchers with a track record in Tropical Medicine and International & Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal

+351 213 652 600

  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Funding

UID/04413/2025 - DOI: 10.54499/UID/04413/2025

UID/PRR/04413/2025 - DOI: 10.54499/UID/PRR/04413/2025

UID/PRR2/04413/2025 - DOI: 10.54499/UID/PRR2/04413/2025

  • Events
  • Research Groups
  • Cross-cutting issues
© Copyright 2026 IHMT-UNL All Rights Reserved.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    UIDB/04413/2020
    UIDP/04413/2020

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.